U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951359) titled 'A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid Tumors' on Nov. 16.
Brief Summary: This study is the first time BNT3211 will be tested in people. It will evaluate different dose levels of BNT3211 in adults to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
BIOLOGICAL: BNT3211
Intravenous infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: BioNTech SE
Disclaimer: Curated by HT Syndication....